Skip to main content
  • linkedin
  • Newsroom
  • Career
  • Contact
Hit enter to search or ESC to close
Close Search
Aboleris PharmaAboleris PharmaAboleris Pharma
search
Menu
  • About us
  • Our Science
  • Patient’s Center
  • Investors
  • search
Category

News

AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
News

AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

AbolerIS Pharma Announces Publication in Molecular Therapy Cell Press Journal of New Preclinical Results Supporting Mechanism of Action of ABO21009, a First-in-Class Anti-CD45RC Antibody, Currently in Phase 1
News

AbolerIS Pharma Announces Publication in Molecular Therapy Cell Press Journal of New Preclinical Results Supporting Mechanism of Action of ABO21009, a First-in-Class Anti-CD45RC Antibody, Currently in Phase 1

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer
News

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
News

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

AbolerIS Pharma Announces Formation of Scientific Advisory Board
News

AbolerIS Pharma Announces Formation of Scientific Advisory Board

AbolerIS is 4 years old!
News

AbolerIS is 4 years old!

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases
News

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

AbolerIS Pharma is one of the laureates of the REACT-EU program 2022
Newssticky

AbolerIS Pharma is one of the laureates of the REACT-EU program 2022

© 2026 Aboleris Pharma. • Privacy • Cookie Policy • Terms and Conditions

Close Menu
  • About us
  • Our Science
  • Patient’s Center
  • Investors
  • Newsroom
  • Career
  • Contact
  • linkedin
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}